FIELD: biotechnology.
SUBSTANCE: disclosed is the use of Leishmania parasites or extracellular vesicles derived from Leishmania parasites for treating neoplastic diseases related to malignant tumours or physiological conditions described by uncontrolled cell growth, and a pharmaceutical composition containing Leishmania parasites or extracellular vesicles obtained from Leishmania parasites, and nanocarrier systems.
EFFECT: inventions provide a wider range of methods for treating a malignant tumor by transferring a specific drug to a target cell and increasing bioavailability of the drug without causing side effects on healthy cells.
24 cl, 20 dwg
Title | Year | Author | Number |
---|---|---|---|
EXO-SOMATIC BIOMARKERS | 2015 |
|
RU2712223C2 |
EXTRACELLULAR VESICLES FOR INHALATION | 2019 |
|
RU2799315C2 |
PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
EXOSOME RECOVERY KIT | 2023 |
|
RU2824663C1 |
EXOSOMES CONTAINING THE THERAPEUTIC POLYPEPTIDES | 2017 |
|
RU2737732C2 |
USE OF PLANT EXOSOMES TO DEMONSTRATE MODULATING EFFECTS ON IMMUNE SYSTEM CELLS | 2019 |
|
RU2806367C2 |
METHOD FOR ISOLATION AND ANALYSIS OF EXOSOMES | 2022 |
|
RU2788198C1 |
USE OF microRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSTICS AND TREATMENT | 2014 |
|
RU2644247C2 |
PRODUCT CONTAINING EXOSOMES OF PLANT ORIGIN | 2018 |
|
RU2764717C2 |
NOVEL METHOD FOR MEASURING AND DESCRIBING MICROVESICLES IN HUMAN FLUIDS | 2009 |
|
RU2520741C2 |
Authors
Dates
2024-03-11—Published
2020-05-08—Filed